Actemra Looks Promising in Scleroderma
Encouraging results were seen for tocilizumab (Actemra) in the treatment of diffuse systemic sclerosis (SSc) in a proof-of-concept study by Christopher P. Denton, MBBS, of University College Londo.
At 24 weeks, a numerically favorable response was seen on modified Rodnan skin scores and lung fibrosis among patients randomized to tocilizumab compared with those receiving placebo. The study is now continuing with a phase III trial that includes a greater number of patients.
news & events
Opinion article: The patient’s journey to a diagnosis
Annelise, a Danish scleroderma patient for many years talks about the patient’s journey towards a diagnosis.
Testimony: António Pereira, music teacher
Meet António Pereira who has lived with and fought against Scleroderma for 40 years.
Testimony: Tânia Vieira, mother
Meet Tânia Vieira who talks about the biggest passion many mothers can relate to.